Insider Trading Activity Vical Inc. (NASDAQ:VICL) – Director Sold 4,000 shares of Stock

Insider Trading Activity For Vical Inc. (NASDAQ:VICL)

Robert C. Merton , Director of Vical Inc. (NASDAQ:VICL) reportedly Sold 4,000 shares of the company’s stock at an average price of 2.24 for a total transaction amount of $8,960.00 SEC Form

Insider Trading History For Vical Inc. (NASDAQ:VICL)

On 8/31/2012 James R Singer, Major Shareholder, bought 310,000 with an average share price of $3.51 per share and the total transaction amounting to $1,088,100.00.

On 9/24/2012 James R Singer, Major Shareholder, bought 154,333 with an average share price of $3.99 per share and the total transaction amounting to $615,788.67.

On 10/15/2012 George J Morrow, Director, bought 6,394 with an average share price of $0.01 per share and the total transaction amounting to $63.94.

On 1/11/2013 Vijay B Samant, CEO, bought 84,600 with an average share price of $0.01 per share and the total transaction amounting to $846.00.

On 1/11/2013 Jill Marie Broadfoot, CFO, bought 27,060 with an average share price of $0.01 per share and the total transaction amounting to $270.60.

On 1/11/2013 Alain P Phd Rolland, VP, bought 22,092 with an average share price of $0.01 per share and the total transaction amounting to $220.92.

On 5/23/2013 Robert C Merton, Director, bought 5,953 with an average share price of $0.01 per share and the total transaction amounting to $59.53.

Analyst Ratings For Vical Inc. (NASDAQ:VICL)
These are 1 Buy RatingThe current consensus rating for Vical Inc. (NASDAQ:VICL) is Buy (Score: 3.00) with a consensus target price of $8.00 , a potential (252.42% upside)

Analyst Ratings History For Vical Inc. (NASDAQ:VICL)

• On 6/23/2015 Roth Capital Downgraded rating Buy to Neutral with a price target of $4.65 to $1.65
• On 11/6/2016 HC Wainwright Reiterated Rating Buy

About Vical Inc. (NASDAQ:VICL)
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Recent Trading Activity for Vical Inc. (NASDAQ:VICL)
Shares of Vical Inc. closed the previous trading session at 2.27 0.00 0.00% with 46,233 shares trading hands.